The Medipattern Corporation

The Medipattern Corporation

April 30, 2008 06:30 ET

Medipattern Enters Breast Surgeon Market

1st B-CAD™ Installation with Breast Surgeon Proves Effective in Treatment Market

TORONTO, ONTARIO--(Marketwire - April 30, 2008) -

Attention: Business/Financial Editors:

The Medipattern Corporation (TSX VENTURE:MKI), an award-winning developer of computer-aided detection (CAD) medical imaging software designed to aid physicians in making better informed biopsy decisions and to permit a higher standard of care for the millions of patients at risk of cancer, is pleased to announce its latest installation with Dr. John Kehoe MD, a private practice Breast Surgeon in Brooklyn, New York. B-CAD increases diagnostic assessment capability and provides structure to reporting for the Breast Cancer Surgery Market, estimated at 242,540 procedures in the United States in 2007 by the American Cancer Society.

"B-CAD can be helpful to breast surgeons. Our care focuses on treatment planning, after the patient has been screened and identified as having a lesion that requires action. To do this well, we really want to assess the characteristics and the extent of that lesion, look to see if there are additional sites and characterize those, too," comments Dr. Kehoe. "B-CAD may be developing into a critical aid in lesion assessment, with the possibility of going beyond classification to provide a well-stated and well-documented report. Initially, I purchased B-CAD specifically for reporting. With anticipated further developments in the B-CAD technology, this devise will provide surgeons like myself with additional high-tech tools to diagnose breast lesions in a timely fashion and will help us continue our assault on breast cancer which affects so many women worldwide."

"Breast Surgeons represent a special market opportunity for CAD in addition to the radiology breast care market which lies within the Medical Imaging Market Sector. Breast surgeons comprise a portion of the Breast Cancer Treatment Market. Frost and Sullivan estimate the breast surgeon market size to be $900 million in 2008," comments Jeff Collins, President, and CEO of The Medipattern Corporation. "Medipattern is displaying B-CAD at the American Society of Breast Surgeons Annual Conference this weekend. We are honored to have Dr. Kehoe as a customer. We congratulate Physician Consultant, Inc. for facilitating this transaction."

Upcoming Events:

Medipattern will participate in the following events:

- American Society of Breast Surgeons (ASBS) Annual Meeting, April 30 to May 4, New York City, NY, USA, exhibiting with partner Physicians Consultants, Inc.

- Advanced Breast Imaging Symposium, May3 to 4, Ankara, Turkey, exhibiting with partner: Teknikel TIC. VE SAN A.S.

- American College of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting, May 3 to 7, New Orleans, LA, USA, exhibiting with partner GE Healthcare

- 33rd National Conference on Breast Cancer, American College of Radiology (ACR) Society of Breast Imaging (SBI), May 8 to 10, Orlando, FL, USA partnering with GE Walker of Tampa, FL and GE Healthcare

- The Leading Edge Ultrasound Conference, May 20 to 23, Atlantic City, NJ, USA exhibiting with partner: GE Healthcare

- V Simposio de La Asociacion Radiologica e Imagenes Diagnosticas De Bogota, May 30 to 31, Bogota, Columbia

- Chicago International Breast Course, September 11 to 14, Chicago, IL, USA

- Radiological Society of North America (RSNA), November 30 to December 5, Chicago, IL, USA

The Medipattern Corporation

Medipattern develops computer-aided detection (CAD) solutions for medical imaging. These products enhance workflow while improving interpretive and diagnostic confidence. The Company's initial clinical applications are B-CAD™ for breast ultrasound and B-CADMRI™. Both have received awards for innovation in the industry. The B-CAD products, part of the Company's CADENZA™ platform, use pattern recognition technology to assist radiologists in their efforts to classify and characterize lesions in medical images. Please visit the company's website at:

B-CAD™ and B-CADMRI™ are trademarks of The Medipattern Corporation.

Medipattern® is a registered mark of The Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.

Contact Information